Spago Nanomedical AB Stock price

Equities

SPAG

SE0004899474

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 07:52:28 2024-03-28 am EDT 5-day change 1st Jan Change
0.29 SEK 0.00% Intraday chart for Spago Nanomedical AB -0.68% -11.31%
Sales 2023 1.2M 112K Sales 2024 * 28.6M 2.67M Capitalization 65.17M 6.09M
Net income 2023 -42M -3.92M Net income 2024 * -33M -3.08M EV / Sales 2023 21.7 x
Net cash position 2023 45.22M 4.23M Net cash position 2024 * 47M 4.39M EV / Sales 2024 * 0.64 x
P/E ratio 2023
-0.76 x
P/E ratio 2024 *
-2.52 x
Employees 13
Yield 2023 *
-
Yield 2024 *
-
Free-Float 77.5%
More Fundamentals * Assessed data
Dynamic Chart
Spago Nanomedical AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Spago Nanomedical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Spago Nanomedical Proceeds to the Next Dose Level in the Phase I/IIa Study Tumorad-01 CI
Spago Nanomedical Announces Positive Top Line Data from a Clinical Phase IIa Study in Patients with Endometriosis CI
Spago Nanomedical Reports Positive Top Line Data from Clinical Phase IIa Study SPAGOPIX-02 in Patients with Endometriosis CI
Spago Nanomedical AB Announces First Patient Dosed in Spago Nanomedical's Clinical Phase I/IIA Study Within the Tumorad(R) Program CI
Spago Nanomedical AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Spago Nanomedical AB Announces Publication of Four New Patent Applications Filed with the European Patent Office CI
Spago Nanomedical Announces Cancer Therapy Approved for Phase I/IIa CI
Spago Nanomedical AB Receives Approval to Initiate the Clinical Phase I/IIa Study with Tumorad in Australia CI
Spago Nanomedical AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Spago Nanomedical Updates on the Clinical Phase IIa Study SPAGOPIX-02 CI
Spago Nanomedical AB Announces Establishment of A Scientific Advisory Board CI
Spago Nanomedical AB Submits Application to Start Tumorad(R) Clinical Phase I/IIa Study CI
Spago Nanomedical AB Elects New Directors CI
More news
1 week-0.68%
Current month-2.68%
1 month-4.61%
3 months-3.01%
6 months-17.14%
Current year-11.31%
More quotes
1 week
0.27
Extreme 0.266
0.30
1 month
0.27
Extreme 0.266
0.38
Current year
0.27
Extreme 0.266
0.43
1 year
0.20
Extreme 0.2
0.90
3 years
0.20
Extreme 0.2
8.82
5 years
0.20
Extreme 0.2
16.50
10 years
0.20
Extreme 0.2
35.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 14-12-31
Director of Finance/CFO 44 19-02-28
Chief Tech/Sci/R&D Officer 62 06-12-31
Members of the board TitleAgeSince
Chairman 66 23-05-09
Director/Board Member 64 23-05-09
Director/Board Member 48 19-05-07
More insiders
Date Price Change Volume
24-03-28 0.29 0.00% 277 900
24-03-27 0.29 +3.57% 148,711
24-03-26 0.28 -0.71% 71,007
24-03-25 0.282 -4.73% 43,936
24-03-22 0.296 +2.07% 58,592

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:52 am EDT

More quotes
Spago Nanomedical publ AB, formerly Spago Imaging publ AB, is a Sweden-based biotechnology company. It specialized in the areas of contrast agents and nanoscale life science research. The Company is involved in three projects: Spago Pix, a nanomaterial developed for use as a cancer selective contrast agent for Magnetic Resonance Imaging (MRI); the therapeutic project Tumorad, using nanoparticles loaded with radionuclides for selective treatment of cancers, which are unsuitable for surgery or external radiation; and Archaea Platin, aimed at delivering of chemotherapeutic substance cisplatin selectively to tumors in order to reduce side effects on healthy tissue. The Company's technology comprises a technology platform IonXgel, which is a nano-sized biocompatible material consisting of polar polymers; a protein-based drug delivery platform, ProtRc; and 3PEG, a platform which enables attachment of polyethylene glycol (PEG) derivatives to small molecules (PEGylation).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Spago Nanomedical AB - Nasdaq Stockholm